Please assess the completion status of the following clinical trial:

Trial Title: Switching the Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) or Protease Inhibitor (PI) to Maraviroc in HIV Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV-1 infected adults (=/+18 years old).~2. Patient having a diagnosis of HIV infection, on stable HAART including 2 NRTI/NtRTIs plus one of the following: 1 PI/ritonavir or ATV/unboosted or 1 NNRTI.~3. Undetectable plasma HIV-1 RNA (VL \< 50 copies/mL) while on HAART.~4. Patient having at least one of the following conditions:~   * Antiretroviral-related gastrointestinal disturbances, or~  * Low patient's satisfaction associated with the current regimen posology (ritonavir use, ritonavir intolerance...), or~  * Any toxicity drug related.~5. Nadir CD4 cell count \> 350 cells/mm3.~6. Absence of resistance mutations in the RT or PR by (TrugeneTM)~7. Good treatment adherence.~8. Voluntary written informed consent.~Exclusion Criteria:~1. Virologic failure to a previous antiretroviral regimen.~2. Any antiretroviral resistance mutation in a previous resistance test.~3. Dual/mixed or X4 viruses detected at any time point, including the pre-treatment ES-Trofile test of the PBMC test done before treatment switch.~4. Acute infections or uncontrolled chronic infection in the 2 months previous to the inclusion.~5. Pregnancy or fertile women willing to be pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- to switch from the NNRTI/PI to maraviroc (Type: EXPERIMENTAL): to switch from the NNRTI/PI to maraviroc
- to continue with the same approach (Type: ACTIVE_COMPARATOR): to continue with the same approach

Based on this trial design, predict the completion outcome and termination type (if applicable).